Viridian Therapeutics, Inc./DE Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $577.00K, a 24.38% decline year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $6.36M, a 176.75% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $763.00K, a 263.33% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for the quarter ending 2025-03-31 was $2.30M, a 174.11% increase year-over-year.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for fiscal 2025 was $12.05M, a 125.54% increase from fiscal 2024.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for fiscal 2024 was $5.34M, a 72.26% decline from fiscal 2023.
- Viridian Therapeutics, Inc./DE stock issued during period, value, stock options exercised for fiscal 2023 was $19.26M.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $577.00K 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $6.36M 10-Q · filed 2026-08-06 | |
| 2025-12-31 | $12.05M 10-K · filed 2026-02-26 | |
| 2025-06-30 | $763.00K 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $2.30M 10-Q · filed 2026-08-06 | |
| 2024-12-31 | $5.34M 10-K · filed 2026-02-26 | |
| 2024-06-30 | $210.00K 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $838.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $19.26M 10-K · filed 2026-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |